CNBCLean R·
Weight loss drug maker sinks 25% after new safety data spooks investors
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Read at CNBC →
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
<iframe src="https://statesidedaily.com/embed/cluster/1351918dff1855021611ab6c85fffaf3c945daac" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Weight loss drug maker sinks 25% after new safety data spooks investors"></iframe>